Millipore’s MEL Cell Lines Advance Human Embryonic Stem Cell Research
Billerica, Massachusetts --- May 14, 2007 --- Millipore Corporation today announced the availability of their MEL cell lines — licensed, low passage, human embryonic stem cells (hES) used in research for the treatment and potential cure of disabling and terminal diseases and conditions. The MEL-1 and MEL-2 hES cell lines have been extensively tested with Millipore’s HEScGRO™ media for human embryonic stem cell culture and are a valuable addition to Millipore’s range of products for hES cell research.
The MEL cell lines, derived by Stem Cell Sciences Ltd in collaboration with Melbourne IVF and the Australian Stem Cell Centre, are under license from the Australian National Health and Medical Research Council. An agreement between Millipore and the Australian Stem Cell Centre in June 2006 made it possible for Millipore to distribute and market these stem cell lines in all countries outside of Australia.
The MEL cell lines are provided at early passage (p10–p12), ideal for maximizing the stable lifespan of the cell line and ensuring extended research time in a stable, pluripotent state. Late passage cell lines can have a limited workable shelf-life as karyotype stability may decrease and pluripotent characteristics may shift to reflect a multipotent state. The MEL cell lines grow as well defined colonies, with compact cells displaying high nuclear to cytoplasmic ratios and prominent nucleoli.
Millipore is the leading provider of mouse embryonic stem cell culture reagents as well as human adult and primary stem cells that are used to foster growth and discovery for disease treatment and development. Millipore’s unique product range comprising optimized media, cell lines, characterization kits and novel, proprietary markers offers an integrated solution for stem cell scientists. Recognizing the diversity of opinions regarding embryonic stem cell research, Millipore is dedicated to conducting its business in an ethical and scientifically responsible manner. Millipore is committed to its customers, shareholders, employees and the global research community in its development of the highest-quality, state-of-the-art products and services for this emerging field.
Millipore’s Bioscience Division provides innovative tools, services and biological reagents that drive advancements in biomedical and academic research as well as support the discovery and development of new pharmaceuticals. The product portfolio has been further enhanced with the 2006 addition of Chemicon, Upstate and Linco product lines, allowing Millipore to provide the most complete offering of life science tools on the market. Our customers work in leading research laboratories across a variety of industries throughout the world. Millipore improves their laboratory productivity and efficiency through optimized workflows. For more information, please contact Millipore Tech Service at 1-800-548-7853 or 951-676-8080 or visit www.millipore.com.
About Millipore
Millipore is a leading provider of products and services that improve productivity in biopharmaceutical manufacturing and in clinical, analytical and research laboratories. The Company is organized in two operating divisions. Its Bioprocess Division helps enables pharmaceutical and biotechnology companies to optimize their manufacturing productivity, ensure the quality of drugs, and scale up the production of difficult-to-manufacture biologics. Its Bioscience division helps to optimize laboratory productivity and workflows. Its products and enabling technologies that are used in the laboratory are essential for the research and development of biologically based life science therapeutics. Millipore has a deep understanding of its customers’ research and manufacturing process needs, and offers reliable and innovative tools, technologies and services. The Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide. For additional information on Millipore Corporation, please visit its website at: www.millipore.com.
About Australian Stem Cell Centre
The Australian Stem Cell Centre is Australia’s Biotechnology Centre of Excellence. The Centre has partnered with nine leading Australian universities and research institutions and brings together a critical mass of outstanding Australian stem cell research that is internationally competitive and recognized. The Centre’s principal objective is to integrate a national multi-institutional research and discovery program to develop treatments for serious disease through the application of stem cells and related technologies. The Australian Stem Cell Centre is funded by the Australian and Victorian Governments. For additional information, please visit www.stemcellcentre.edu.au.
About Stem Cell Sciences
Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company, established in Melbourne, Australia in 1994, providing products in the burgeoning stem cell research and drug discovery markets, in addition to the targeted development of cell-based therapies for neurodegenerative disease and injury. The Company has established a leading intellectual property (IP) and technology portfolio that enables the commercial application of stem cells in drug discovery, providing the Company with early-stage revenue streams and technology development for at scale cell production of SCS cell-based therapeutics. SCS operates as a group of independent operations with laboratories in Scotland, Japan and Australia, each of which is affiliated with an academic centre of excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh, UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem Cell Centre, Melbourne, Australia. For further information on the company please visit www.stemcellsciences.com.
Millipore is a registered trademark and HEScGRO is a trademark of Millipore Corporation.
MILLIPORE NEWS
For immediate release
Media Contact:
Lauren Nolan
Communications Specialist
Millipore Corporation
978-762-5080
lauren_nolan@millipore.com
可持续性发展是机会，也是责任。更多信息请查看Millipore2008 可持续性发展报告。
全球办公室
当地应用专员
Millipore支持
客户服务
全球办事处
建议&反馈
多媒体使用要求